M2 Archive: Preview
You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.
Return to Archives
New Search
Inovio Biomedical Corp secures Korean approval to begin clinical trials for SynCon universal flu vaccine
DNA vaccines developer Inovio Biomedical Corp (NYSE Amex:INO) declared on Tuesday that its affiliate VGX International Inc (Korea:011000) has received approval in Korea to start a Phase I clinical trial for Inovio's SynCon preventive DNA vaccine (VGX-3400) targeting H5N1 avian influenza.
...
If you want to view the full text of this story, you must first purchase archive retrieval credits.